In comparison, the efficacy of ATM inhibitors for the treatment of prostate cancer has not been extensively studied; however, there are three ATM inhibitors (M354, AZD0516, and AZD1390) undergoing clinical investigation. This evidence concerns the gene ATM and prostate carcinoma.